Oxymorphone

BreastfeedingGeriatricPediatric
  • TRADE NAME: Opana (Endo)
  • INDICATIONS: Pain (moderate to severe)
  • CLASS: Analgesic, Opiate agonist
  • HALF-LIFE: 7–9 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Anticholinergics, Buprenorphine, Butorphanol, Cimetidine, CNS depressants, MAO inhibitors, Nalbuphine, Pentazocine

PREGNANCY CATEGORY: C

Contra-indicated in patients with a known hypersensitivity to morphine analogs such as codeine; in patients with respiratory depression, except in monitored settings and in the presence of resuscitative equipment; in patients with acute or severe bronchial asthma or hypercarbia; in any patient who has or is suspected of having paralytic ileus; and in patients with moderate or severe hepatic impairment.

Our database has 61 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of oxymorphone in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top